We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
International Markets and Haemonetics (HAE): A Deep Dive for Investors
Read MoreHide Full Article
Have you evaluated the performance of Haemonetics' (HAE - Free Report) international operations during the quarter that concluded in September 2026? Considering the extensive worldwide presence of this provider blood management systems for health care providers and blood collectors, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.
In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For investors, understanding a company's reliance on overseas markets has become increasingly crucial, as it offers insights into the company's sustainability of earnings, ability to tap into diverse economic cycles and overall growth potential.
Presence in international markets can act as a hedge against domestic economic downturns and provide access to faster-growing economies. However, this diversification also brings complexities due to currency fluctuations, geopolitical risks and differing market dynamics.
While analyzing HAE's performance for the last quarter, we found some intriguing trends in revenues from its overseas segments that Wall Street analysts commonly model and monitor.
The company's total revenue for the quarter amounted to $357.76 million, showing rise of 9.3%. We will now explore the breakdown of HAE's overseas revenue to assess the impact of its international operations.
A Dive into HAE's International Revenue Trends
Of the total revenue, $46.61 million came from Europe during the last fiscal quarter, accounting for 13%. This represented a surprise of +4.92% as analysts had expected the region to contribute $44.42 million to the total revenue. In comparison, the region contributed $45.53 million, or 13.4%, and $42.97 million, or 13.1%, to total revenue in the previous and year-ago quarters, respectively.
During the quarter, Other International contributed $3.59 million in revenue, making up 1% of the total revenue. When compared to the consensus estimate of $2.67 million, this meant a surprise of +34.41%. Looking back, Other International contributed $2.99 million, or 0.9%, in the previous quarter, and $3.68 million, or 1.1%, in the same quarter of the previous year.
Japan generated $16.09 million in revenues for the company in the last quarter, constituting 4.5% of the total. This represented a surprise of -7% compared to the $17.3 million projected by Wall Street analysts. Comparatively, in the previous quarter, Japan accounted for $12.86 million (3.8%), and in the year-ago quarter, it contributed $18.01 million (5.5%) to the total revenue.
International Market Revenue Projections
The current fiscal quarter's total revenue for Haemonetics, as projected by Wall Street analysts, is expected to reach $357.56 million, reflecting an increase of 5.5% from the same quarter last year. The breakdown of this revenue by foreign region is as follows: Europe is anticipated to contribute 12.6% or $45.14 million, Other International 0.8% or $2.76 million and Japan 4.9% or $17.34 million.
Analysts expect the company to report a total annual revenue of $1.41 billion for the full year, marking an increase of 5.9% compared to last year. The expected revenue contributions from Europe, Other International and Japan are projected to be 13% ($183.6 million), 0.9% ($12.74 million) and 4.7% ($66.33 million) of the total revenue, in that order.
Closing Remarks
Haemonetics' reliance on international markets for revenues offers both opportunities and risks. Hence, keeping an eye on its international revenue trends could significantly help forecast the company's prospects.
In an era of growing international ties and escalating geopolitical disputes, financial analysts on Wall Street pay keen attention to these developments to fine-tune their earnings estimations for businesses operating across borders. It's important to note, however, that a range of additional variables, like a company's local market status, also play a crucial role in shaping these forecasts.
At Zacks, we place significant importance on a company's evolving earnings outlook. This is based on empirical evidence demonstrating its strong influence on a stock's short-term price movements. Invariably, there exists a positive relationship -- an upward revision in earnings estimates is typically mirrored by a rise in the stock price.
The Zacks Rank, our proprietary stock rating tool, comes with an externally validated impressive track record. It effectively utilizes shifts in earnings projections to act as a dependable barometer for forecasting short-term stock price trends.
A Review of Haemonetics' Recent Stock Market Performance
Over the past month, the stock has seen an increase of 1% in its value, whereas the Zacks S&P 500 composite has posted a decrease of 5.6%. The Zacks Medical sector, Haemonetics' industry group, has ascended 9.4% over the identical span. In the past three months, there's been an increase of 32.1% in the company's stock price, against a fall of 4.1% in the S&P 500 index. The broader sector has increased by 8% during this interval.
View the Zacks #1 Rank List
Image: Bigstock
International Markets and Haemonetics (HAE): A Deep Dive for Investors
Have you evaluated the performance of Haemonetics' (HAE - Free Report) international operations during the quarter that concluded in September 2026? Considering the extensive worldwide presence of this provider blood management systems for health care providers and blood collectors, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.
In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For investors, understanding a company's reliance on overseas markets has become increasingly crucial, as it offers insights into the company's sustainability of earnings, ability to tap into diverse economic cycles and overall growth potential.
Presence in international markets can act as a hedge against domestic economic downturns and provide access to faster-growing economies. However, this diversification also brings complexities due to currency fluctuations, geopolitical risks and differing market dynamics.
While analyzing HAE's performance for the last quarter, we found some intriguing trends in revenues from its overseas segments that Wall Street analysts commonly model and monitor.
The company's total revenue for the quarter amounted to $357.76 million, showing rise of 9.3%. We will now explore the breakdown of HAE's overseas revenue to assess the impact of its international operations.
A Dive into HAE's International Revenue Trends
Of the total revenue, $46.61 million came from Europe during the last fiscal quarter, accounting for 13%. This represented a surprise of +4.92% as analysts had expected the region to contribute $44.42 million to the total revenue. In comparison, the region contributed $45.53 million, or 13.4%, and $42.97 million, or 13.1%, to total revenue in the previous and year-ago quarters, respectively.
During the quarter, Other International contributed $3.59 million in revenue, making up 1% of the total revenue. When compared to the consensus estimate of $2.67 million, this meant a surprise of +34.41%. Looking back, Other International contributed $2.99 million, or 0.9%, in the previous quarter, and $3.68 million, or 1.1%, in the same quarter of the previous year.
Japan generated $16.09 million in revenues for the company in the last quarter, constituting 4.5% of the total. This represented a surprise of -7% compared to the $17.3 million projected by Wall Street analysts. Comparatively, in the previous quarter, Japan accounted for $12.86 million (3.8%), and in the year-ago quarter, it contributed $18.01 million (5.5%) to the total revenue.
International Market Revenue Projections
The current fiscal quarter's total revenue for Haemonetics, as projected by Wall Street analysts, is expected to reach $357.56 million, reflecting an increase of 5.5% from the same quarter last year. The breakdown of this revenue by foreign region is as follows: Europe is anticipated to contribute 12.6% or $45.14 million, Other International 0.8% or $2.76 million and Japan 4.9% or $17.34 million.Analysts expect the company to report a total annual revenue of $1.41 billion for the full year, marking an increase of 5.9% compared to last year. The expected revenue contributions from Europe, Other International and Japan are projected to be 13% ($183.6 million), 0.9% ($12.74 million) and 4.7% ($66.33 million) of the total revenue, in that order.
Closing Remarks
Haemonetics' reliance on international markets for revenues offers both opportunities and risks. Hence, keeping an eye on its international revenue trends could significantly help forecast the company's prospects.
In an era of growing international ties and escalating geopolitical disputes, financial analysts on Wall Street pay keen attention to these developments to fine-tune their earnings estimations for businesses operating across borders. It's important to note, however, that a range of additional variables, like a company's local market status, also play a crucial role in shaping these forecasts.
At Zacks, we place significant importance on a company's evolving earnings outlook. This is based on empirical evidence demonstrating its strong influence on a stock's short-term price movements. Invariably, there exists a positive relationship -- an upward revision in earnings estimates is typically mirrored by a rise in the stock price.
The Zacks Rank, our proprietary stock rating tool, comes with an externally validated impressive track record. It effectively utilizes shifts in earnings projections to act as a dependable barometer for forecasting short-term stock price trends.
Haemonetics, bearing a Zacks Rank #3 (Hold), is expected to mirror the broader market's movements in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
A Review of Haemonetics' Recent Stock Market Performance
Over the past month, the stock has seen an increase of 1% in its value, whereas the Zacks S&P 500 composite has posted a decrease of 5.6%. The Zacks Medical sector, Haemonetics' industry group, has ascended 9.4% over the identical span. In the past three months, there's been an increase of 32.1% in the company's stock price, against a fall of 4.1% in the S&P 500 index. The broader sector has increased by 8% during this interval.